

17 November 2025

## Treatment of Melanoma

I have a freedom of information request regarding the treatment of melanoma.

**1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :**

- Cobimetinib <5
- Dabrafenib <5
- Dabrafenib + Trametinib 29
- Dacarbazine <5
- Denosumab <5
- Encorafenib + Binimetinib 30
- Ipilimumab monotherapy <5
- Ipilimumab + Nivolumab 9
- Nivolumab monotherapy 17
- Nivolumab + Relatlimab 5
- Pembrolizumab 54
- Trametinib <5
- Vemurafenib <5
- Vemurafenib + Cobimetinib <5
- Other active systemic anti-cancer therapy 6
- Palliative care only Information not available

**2. In the last 3 months, how many patients have been initiated\* on the following agents for treatment for melanoma? \*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

- Ipilimumab (monotherapy) <5
- Nivolumab (monotherapy) <5
- Nivolumab AND Ipilimumab (combination) 8
- Nivolumab AND Relatlimab <5
- Pembrolizumab 14
- Any Targeted Therapy:
  - Dabrafenib
  - Dabrafenib AND Trametinib 7
  - Encorafenib AND Binimetinib 6
  - Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib
- Other active systemic anti-cancer therapy <5

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.